A Study Testing the Drug Zanzalintinib for Meningioma That Has Come Back or Is Growing
Original title: A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a middle stage trial, so the drug is still being tested to see if it works.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This trial is testing a drug called zanzalintinib in people whose meningioma has come back or keeps growing.
Who this trial is for. This trial is for people with meningioma that has come back or is getting worse. It is for people whose tumor did not get better with standard treatments. The trial is testing a drug called zanzalintinib.
Where it stands. The trial is measuring how well zanzalintinib works against these tumors. It is also measuring how safe the drug is. Those answers are not in yet. The trial has not reported results.
What this means, and what it doesn't
What it could mean: There is no proof yet that this drug helps. Doctors are still gathering that information. If your meningioma has come back or is growing after standard treatment, you could ask your care team about this trial. They can tell you if it makes sense to look into.
What it doesn't mean: This does not mean zanzalintinib works for meningioma. A trial is a test, not a proven treatment. Joining a trial is not a guarantee that you will be helped. The drug may not help, and it may cause side effects. This is not a promise of a cure. Whether anyone can join is decided by the trial team.
Source: ClinicalTrials.gov, July 27, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.